Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8653846 | 0.98 | GPR84 (0.46) | GPR84CRBNCYP2C9CYP2C19PKM | |
| SCHEMBL954608 | 0.88 | CRBN (0.46) | GPR84CRBNPKM | |
| SCHEMBL8656959 | 0.81 | CRBN (0.48) | CRBNPKM | |
| Methimazole SCHEMBL8813156 | 0.73 | CRBN (0.39) | GPR84CRBNPKM | |
| SCHEMBL7837324 | 0.71 | DUT (0.56) | CRBNPKM | |
| SCHEMBL17372138 | 0.70 | DUT (0.55) | CYP2C9CYP2C19PKMCYP1A2 | |
| SCHEMBL18475004 | 0.70 | GPR84 (0.44) | GPR84CRBNCYP2C19PKMSMN1; SMN2 | |
| SCHEMBL22327126 | 0.70 | GPR84 (0.44) | GPR84CRBNCYP2C19PKMSMN1; SMN2 | |
| SCHEMBL18479912 | 0.70 | GPR84 (0.44) | GPR84CRBNCYP2C19PKMSMN1; SMN2 | |
| SCHEMBL6864606 | 0.69 | DUT (0.57) | CRBNPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109661224-B | Compounds for reducing melanin content in cells | 联合利华知识产权控股有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-3509566-B1 | COMPOUNDS FOR REDUCING CELLULAR MELANIN CONTENT | UNILEVER NV (NL) | 2020-11-04 | — | — | EP | disclosed |
| EP-3509566-A1 | COMPOUNDS FOR REDUCING CELLULAR MELANIN CONTENT | Unilever N.V. (NL) | 2019-07-17 | — | — | EP | disclosed |
| CN-107915684-A | A kind of synthetic method of uncleosides as antiviral agents intermediate thiopyrimidine ketone derivatives | 陈国妃 | 2018-04-17 | — | — | CN | disclosed |
| WO-2018046243-A1 | COMPOUNDS FOR REDUCING CELLULAR MELANIN CONTENT | UNILEVER N.V. (NL) | 2018-03-15 | — | — | WO | disclosed |
| EP-3060194-A1 | SKIN LIGHTENING COMPOSITION | Unilever PLC (GB) | 2016-08-31 | — | — | EP | disclosed |
| US-20160243015-A1 | SKIN LIGHTENING COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-08-25 | — | — | US | disclosed |
| WO-2015059001-A1 | SKIN LIGHTENING COMPOSITION | UNILEVER PLC (GB) | 2015-04-30 | — | — | WO | disclosed |
| CN-1903203-A | Application of derivative of polysubstituted acyl thiourea pyrimidine for preparing antiviral medicine | UNIV FUDAN (CN) | 2007-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243015-A1 | SKIN LIGHTENING COMPOSITION | TYR, MC1R, MITF | GPR84 1329/4885CRBN 4113/4885CYP2C9 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.